Pharma BD Deal Intelligence
A $5.05B collaboration built entirely on Arcus's anti-TIGIT thesis, and that thesis collapsed: both Phase 3 trials (STAR-221, STAR-121) were stopped for futility, and Gilead let its option period lapse in 2026 rather than continue. Arcus is left refocusing on an unproven HIF-2a inhibitor.
Gilead Sciences is paying $375 million in cash and $200 million in equity for a 10-year option-based partnership with Arcus Biosciences covering the company's…
Gilead Sciences will pay up to $5 billion to access a portfolio of next-generation cancer drugs from Arcus Biosciences, including a closely-watched anti-TIGIT…
Gilead and Arcus continue to differentiate their domvanalimab anti-TIGIT program from Roche's failed tiragolumab and Merck's mixed vibostolimab readouts,…
Source summaries from our enrichment pipeline; follow links for originals.
All 18 sources with sentiment breakdown →
Gilead Sciences and Arcus Biosciences entered a 10-year collaboration to develop and commercialize next-generation immuno-oncology therapies. Gilead paid $375M upfront and made a $200M equity investment, with up to $4.475B in option exercise fees and milestone payments. The deal covers Arcus's pipeline of anti-TIGIT (domvanalimab), anti-PD-1, anti-CD73, and other IO assets. This was a partnership with an equity stake (later ~33%), not an acquisition. The anti-TIGIT thesis subsequently collapsed: the Phase 3 STAR-221 (upper GI) study was discontinued for futility in December 2025 and STAR-121 (1L NSCLC) was discontinued for futility in April 2026. On April 20, 2026 Gilead declined the option-continuation payment, ending its option period on July 14, 2026 and forgoing options to Arcus's CCR6/CD89/CD40L programs while retaining existing options on AB801, AB598, AB102 and a TNF inhibitor. Arcus has refocused on its wholly-owned HIF-2a inhibitor casdatifan (Phase 3 PEAK-1 in ccRCC).
236K US cases/yr · $175.0B Global oncology therapeutics market 2020 · ~$5.05B Total deal BD value (incl. $375M upfront + $200M equity + up to $4.475B option/milestones)
The Gilead-Arcus 10-year collaboration covers a broad next-generation immuno-oncology pipeline spanning anti-TIGIT, anti-PD-1, anti-CD73, anti-CD39, and anti-A2aR adenosine receptor programs across NSCLC, gastric/GEJ adenocarcinoma, hepatocellular carcinoma, colorectal cancer, and pancreatic cancer. NSCLC affects approximately 236,000 new U.S. patients per year (American Cancer Society 2020), with PD-(L)1-eligible Stage IV non-squamous adenocarcinoma representing roughly 70% of incident cases. Colorectal cancer affects approximately 148,000 new U.S. patients annually with the metastatic MSS subset (~85%) representing the IO-resistant unmet need where TIGIT and adenosine pathway combinations are being explored. Pancreatic adenocarcinoma affects ~57,000 patients annually with historically poor checkpoint response, an area where anti-CD73 small molecules like quemliclustat are being tested in combination with chemotherapy backbones. Anti-TIGIT antibodies like domvanalimab represent the most-watched combination class in PD-1-anchored IO franchises after Roche/Genentech's Phase 2 CITYSCAPE NSCLC data lifted the field in early 2020. Anti-CD73 small molecules and antibodies disrupt the adenosine immunosuppression axis. WAC pricing for branded checkpoint inhibitors ranges $13K-15K per month with treatment durations of 1-3 years for responding patients.
The next-generation IO competitive landscape is the most contested space in oncology. Anti-TIGIT antibodies are led by tiragolumab (Roche/Genentech, Phase 3 SKYSCRAPER program in NSCLC, gastric, esophageal — multiple Phase 3 failures by 2022 reset class expectations), vibostolimab (MK-7684, Merck Phase 3), ociperlimab (BeiGene Phase 3), domvanalimab (AB154, Arcus/Gilead Phase 3 ARC-7/ARC-10), and AGEN1777 (Agenus). Anti-CD73 includes oleclumab (MEDI9447, AstraZeneca), quemliclustat/AB680 (Arcus), and uliledlimab (I-Mab). Anti-A2aR (adenosine receptor) includes ciforadenant (CPI-444, Corvus) and etrumadenant (AB928, Arcus). The anchor PD-(1)/PD-L1 backbone remains pembrolizumab (Keytruda Merck), nivolumab (Opdivo BMS), atezolizumab (Tecentriq Roche), and durvalumab (Imfinzi AstraZeneca). Gilead's TIGIT-anchored bag now competes most directly against the Roche/Merck/BeiGene Phase 3 stacks, with domvanalimab differentiating on Fc-silent design (versus Fc-active tiragolumab/vibostolimab) — a thesis subject to ongoing clinical debate after multiple TIGIT Phase 3 failures.
200K US cases/yr · $30.0B Global NSCLC Market (2024)
NSCLC (~85% of lung cancer). IO dominates first-line. Gilead/Arcus collaboration targets next-gen IO combos (domvanalimab anti-TIGIT + zimberelimab anti-PD-1).
Merck (Keytruda $25B+), AZ (Tagrisso $5B+, Imfinzi), BMS (Opdivo). Anti-TIGIT class has had mixed results (Roche tiragolumab failed).
64K US cases/yr · $3.0B Global Pancreatic Cancer Market (2024)
Worst prognosis of major cancers. Chemotherapy backbone with limited IO/targeted options. Novel combinations the next frontier.
BMS (Abraxane), Ipsen (Onivyde), generic FOLFIRINOX. KRAS G12D programs in development. Significant unmet need.
Gilead Sciences Inc. completed its acquisition of Arcus Biosciences, Inc. for $5B. Gilead Sciences and Arcus Biosciences entered a 10-year collaboration to develop and commercialize next-generation immuno-oncology therapies.
$320M equity + $100M option continuation payment. Reflects financial performance following Gilead Sciences Inc.'s $5B acquisition of Arcus Biosciences, Inc..
Arcus refocused on HIF-2a inhibitor + cabozantinib in RCC after TIGIT failures. Part of Gilead Sciences Inc.'s $5B deal to acquire Arcus Biosciences, Inc..
Phase 3 STAR-221 (1L HER2-negative gastric/esophageal) was discontinued for futility on the IDMC's recommendation; the domvanalimab + zimberelimab + chemo regimen did not improve overall survival vs nivolumab + chemo. Arcus refocused R&D on casdatifan. (Collaboration + 33% equity stake -- not an acquisition.)
Phase 3 STAR-121 of domvanalimab + zimberelimab + chemo vs pembrolizumab + chemo in first-line metastatic NSCLC was discontinued on the IDMC's recommendation after a pre-planned futility analysis; the companion EDGE-Lung study was also halted. This completed the failure of the anti-TIGIT program at the center of the Gilead collaboration.
Gilead elected not to make the option-continuation payment, ending the period for its option rights on July 14, 2026. Gilead forgoes options to Arcus's early-stage CCR6, CD89 and CD40L programs but retains its existing time-limited options to AB801, AB598, AB102 and an investigational TNF small-molecule inhibitor -- a material narrowing of the 2020 collaboration.
See timeline for full assessment. Assessment of Gilead Sciences Inc.'s $5B acquisition of Arcus Biosciences, Inc. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Arcus Biosciences, Inc. (this deal) | 2020 | $5.0B | 46 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2020 deals · Gilead Sciences Inc. deals · Oncology deals